SUMMUS MEDICAL LASER® LAUNCHES REAL-WORLD EVIDENCE PROGRAM
Summus' RWE Program builds upon recent FDA guidance on the use of RWE to support regulatory decision-making for medical devices. The program is based on Circles, RegenMed's patented, technical platform and turnkey process for generating clinical, scientific, and financial value from real-world evidence. The program's initial Circles will collect and analyze real-world evidence on peripheral neuropathy from dozens of providers in the
Dr.
About Summus Medical Laser:
Summus Medical Laser is a renowned leader in the laser therapy industry, providing laser products to over 51 countries that have resulted in millions of treatments performed worldwide. With a strong commitment to continued innovation, reliable stateside customer service, and growing brand awareness, Summus Medical Laser is devoted to empowering healthcare professionals to provide optimal patient care through the use of advanced laser therapy. To learn more, visit https://www.summuslaser.com.
About RegenMed:
RegenMed is the category leader in developing and executing Real-World Evidence Programs for provider groups, medical societies, and medical product manufacturers around the world. Those RWE Programs are redefining and democratizing impactful medical research. More information can be found at https://www.rgnmed.com/.
Click here to review the initial
View original content to download multimedia:https://www.prnewswire.com/news-releases/summus-medical-laser-launches-real-world-evidence-program-302118386.html
SOURCE Summus Medical Laser
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Democratic Republic of Congo Launches Landmark "Invest in the DRC" Advertising Campaign in United States
- Scale Law Firm AI Appoints Tima Mousavi to Lead AI Education and Training for Lawyers
- Ethereum News: Why Pepeto’s $10.3 Million Presale Grows While ETH Restructures
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share